# AEON Biopharma, Inc. (AEON) · Edgar & Edgarette company card

> Figures from the company's own SEC filings.

SEC CIK 1837607 · fiscal year ended — · 0 audited years read · [page](https://www.pops4.com/boards/company/AEON) · [JSON](https://www.pops4.com/boards/company/AEON.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | — |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | — |
| Net margin | — |
| Operating cash flow | — |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | — |
| Total assets | — |
| Total equity | — |
| Equity ÷ assets | — |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures


## Edgarette's reading

The filings carry no annual revenue line Edgarette can read (common for banks and insurers, which report income differently). Nothing weighed, nothing guessed.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-04-03 ([filing](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000025/0001837607-26-000025-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-03-09 ([filing](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000009/0001837607-26-000009-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-26 · [filing](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000074/0001837607-26-000074-index.htm)
- 8-K · filed 2026-10-23 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000071/0001837607-26-000071-index.htm)
- 8-K · filed 2026-09-30 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/0001837607-26-000064-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000062/0001837607-26-000062-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/0001837607-26-000061-index.htm)
- 8-K · filed 2026-08-03 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/0001837607-26-000057-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001837607.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1837607

## Cite

POPS4, Edgar & Edgarette: AEON Biopharma, Inc. (AEON) company card, from the company's own SEC filings, accessed 2026-10-27, https://www.pops4.com/boards/company/AEON. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.